Drug intelligence / Profile preview

ketoprofen + doxycycline

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral, Topical

Overview

Ketoprofen + doxycycline is a combination of a nonsteroidal anti-inflammatory drug (NSAID) and a tetracycline antibiotic. Ketoprofen inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin production to provide anti-inflammatory, analgesic, and antipyretic effects. Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the association of aminoacyl-tRNA with the ribosomal A site. This combination has been studied for treating non-gonococcal urethritis (NGU) with evidence suggesting it may reduce recurrence rates compared to doxycycline monotherapy.

Targets

Bacterial RibosomePTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on ketoprofen + doxycycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketoprofen + doxycycline.

Explore the full profile